{"id":"W2546600532","doi":"10.1111/jdv.14033","title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3","year":2016,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":true,"ca_institutions":"Guenther Dermatology Research Centre; Western University","funders":"Universidade Católica de Brasília; Regeneron Pharmaceuticals; Roche; American Society for Parenteral and Enteral Nutrition; Novartis; Merck; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer; Baxalta; Schering-Plough; AbbVie; Biogen Idec","keywords":"Ixekizumab; Medicine; Etanercept; Placebo; Psoriasis; Plaque psoriasis; Dermatology; Internal medicine; Psoriatic arthritis; Secukinumab; Tumor necrosis factor alpha; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009610186,0.0003397067,0.001960027,0.0001664053,0.0001616659,0.00001351141,0.0006543212,0.0002613815,0.000008992361],"category_scores_gemma":[0.00107658,0.0001378909,0.0001905423,0.0001226275,0.000745652,0.00016666,0.0002746683,0.000251043,0.000005235852],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003314095,"about_ca_system_score_gemma":0.0000854121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000061102,"about_ca_topic_score_gemma":0.00002365008,"domain_scores_codex":[0.9944721,0.003496363,0.001299212,0.0003218995,0.00008086536,0.0003295409],"domain_scores_gemma":[0.9935927,0.004331086,0.001675541,0.0002381247,0.0001096189,0.00005290683],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6851841,0.002029878,0.1881757,0.00003349352,0.01086272,0.0000732265,0.0042211,0.00003546114,0.01206132,0.001009661,0.004704874,0.09160842],"study_design_scores_gemma":[0.8390345,0.0007301752,0.1321071,0.000404235,0.001878429,0.0005305807,0.000217289,0.000004157938,0.02106589,0.001238465,0.002607405,0.0001817873],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889425,0.006104585,0.00002116742,0.003078045,0.0004103987,0.0008253246,0.0001670138,0.000005670538,0.0004453058],"genre_scores_gemma":[0.9969981,0.002003893,0.0001442058,0.0002873851,0.00005781074,0.00001880937,0.000006732343,0.00002153116,0.0004614838],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1538504,"threshold_uncertainty_score":0.5623029,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01729171059612685,"score_gpt":0.2399895872063726,"score_spread":0.2226978766102457,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}